Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 9:13:823618.
doi: 10.3389/fimmu.2022.823618. eCollection 2022.

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

Hirva Mamdani  1 , Sandro Matosevic  2 , Ahmed Bilal Khalid  3 , Gregory Durm  4 , Shadia I Jalal  4
Affiliations
Review

Immunotherapy in Lung Cancer: Current Landscape and Future Directions

Hirva Mamdani et al. Front Immunol. .

Abstract

Over the past decade, lung cancer treatment has undergone a major paradigm shift. A greater understanding of lung cancer biology has led to the development of many effective targeted therapies as well as of immunotherapy. Immune checkpoint inhibitors (ICIs) have shown tremendous benefit in the treatment of non-small cell lung cancer (NSCLC) and are now being used as first-line therapies in metastatic disease, consolidation therapy following chemoradiation in unresectable locally advanced disease, and adjuvant therapy following surgical resection and chemotherapy in resectable disease. Despite these benefits, predicting who will respond to ICIs has proven to be difficult and there remains a need to discover new predictive immunotherapy biomarkers. Furthermore, resistance to ICIs in lung cancer is frequent either because of a lack of response or disease progression after an initial response. The utility of ICIs in the treatment of small cell lung cancer (SCLC) remains limited to first-line treatment of extensive stage disease in combination with chemotherapy with modest impact on overall survival. It is thus important to explore and exploit additional targets to reap the full benefits of immunotherapy in the treatment of lung cancer. Here, we will summarize the current state of immunotherapy in lung cancer, discuss novel targets, and explore the intersection between DNA repair defects and immunotherapy.

Keywords: DNA repair; cellular therapy; engineered immune cells; immune checkpoint inhibitors; immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have following conflicts of interest within the past 2 years, none of which influenced the work being submitted. HM: Advisory role – Zentalis. GD: Research grant - BMS, AstraZeneca, Merck; Honoraria - AstraZeneca, Curio Science. SJ: Research grant - AstraZeneca, Astex, Tesaro; Consultant – Adaptimmune. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Novel immunotherapy targets and intersection with DNA repair.
See this image and copyright information in PMC

References

    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med (2020) 383(7):640–9. doi: 10.1056/NEJMoa1916623 - DOI - PMC - PubMed
    1. Network NCC . Non-Small Cell Lung Cancer (Version 7.2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
    1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. . Signatures of Mutational Processes in Human Cancer. Nature (2013) 500(7463):415–21. doi: 10.1038/nature12477 - DOI - PMC - PubMed
    1. Pardoll DM. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat Rev Cancer (2012) 12(4):252–64. doi: 10.1038/nrc3239 - DOI - PMC - PubMed
    1. The Nobel Prize in Physiology or Medicine 2018 [Press Release] Stockholm: The Nobel Assembly at Karolinska Institutet; 2018 (2018). Available at: https://www.nobelprize.org/prizes/medicine/2018/press-release/.

MeSH terms

Substances